Skip to content
Study details
Enrolling now

Effects of Dronabinol in Opioid Maintained Patients

Yale University
NCT IDNCT04025359ClinicalTrials.gov data as of Apr 2026
Phase

EARLY_PHASE1

Target enrollment

36

Study length

about 7.3 years

Ages

18–70

Locations

1 site in CT

About this study

This trial is testing if dronabinol helps people who are currently taking opioids for chronic pain. Participants will receive either dronabinol or a placebo, and their opioid-related outcomes will be measured using various tests like pain sensitivity measurements, cognitive assessments, and urine toxicology testing.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Dronabinol
  • 2.Take Placebo
PhaseEARLY_Phase 1
DrugDronabinol
Routeoral
Primary goalPain sensitivity, measured by the Cold Pressor Test (CPT)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low10%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

dronabinol

Drug routes

oral (Oral Capsule)

Endpoints

Primary: Pain sensitivity, measured by the Cold Pressor Test (CPT)., Pain sensitivity, measured by the Short form of the McGill Pain Questionnaire (SF-MPQ).